Skip to content

20-069 - Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

Status: open

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation (EMERALD-2)

Treatment for Hepatocellular Carcinoma

Contact Us Or call (251) 445-9834

Description

This clinical trial is for patients who have been diagnosed with a type of liver cancer (Hepatocellular Carcinoma (HCC) and patients are at high risk of recurrence after curative hepatic resection or ablation. The reason for the study is to find more effective treatment for HCC after curative resection or ablation.

Sponsors

This trial is sponsored by Astra Zeneca.

Providers Associated With This Trial

Principle Investigator

This link will open in a new tab or window.